Valion Bio
VBIO
11 hedge funds and large institutions have $216K invested in Valion Bio in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
397% more capital invested
Capital invested by funds: $43.4K → $216K (+$172K)
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
120% more funds holding
Funds holding: 5 → 11 (+6)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$248K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$224K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$53.3K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$12.6K |
| 5 |
E
Ergoteles
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$17K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.05K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$8 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSWM
1
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
| $90.6K | +$248K | +353 | New |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $81.6K | +$224K | +319 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $20.1K | +$53.3K | +76 | +3,800% |
|
|
BFM
4
Boothbay Fund Management
New York
| $4.52K | +$12.6K | +18 | New |
|
|
E
5
Ergoteles
New York
| $4.28K | +$11.9K | +17 | New |
|
|
HF
6
HRT Financial
New York
| $4K | +$11.2K | +16 | New |
|
|
OGC
7
One68 Global Capital
New York
| $2.88K | +$7.72K | +11 | New |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $2.2K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.93K | +$5.61K | +8 | New |
|
11
Goldman Sachs
New York
| $1.57K | +$4.21K | +6 | New |
|
12
Wells Fargo
San Francisco,
California
| $7 | – | – | – |
|
|
13
Renaissance Technologies
New York
| – | -$17K | -15 | Closed |
|
|
TSS
14
Two Sigma Securities
New York
| – | -$8.05K | -7 | Closed |
|
|
15
Bank of America
Charlotte,
North Carolina
| – | -$8 | – | – |
|
VBIO Hedge Fund Activity: Q1 2023 in Review
11 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2023, worth a combined $216K — up 397% from $43.4K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VBIO positions and 2 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sheets Smith Wealth Management, opening a new position worth an estimated $248K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $17K sold.
- 11 institutional investors held Valion Bio (VBIO) as of Q1 2023, up from 5 in Q4 2022.
- Funds reported $216K of Valion Bio stock for Q1 2023, up 397% quarter-over-quarter.
- 8 funds opened new Valion Bio positions in Q1 2023 and 2 closed out, a net change of +6 holders.
- The largest Valion Bio buyer in Q1 2023 was Sheets Smith Wealth Management, an estimated $248K added.
- The largest Valion Bio seller in Q1 2023 was Renaissance Technologies, an estimated $17K sold.
Based on aggregated 13F filings for Q1 2023.